Evidence base: Human papillomavirus

A summary of the evidence behind the primary care management of human papillomavirus.

Colposcopy showing a lesion on the cervix caused by HPV (Photograph: SPL)
Colposcopy showing a lesion on the cervix caused by HPV (Photograph: SPL)

Clinical trials

  • Kelly RS, Patnick J, Kitchener HC et al on behalf of the NHSCSP HPV Special Interest Group. HPV testing as a triage for borderline or mild dyskaryosis on cervical cytology: results from the Sentinel Sites study. Br J Cancer 2011: 1-6. doi:10.1038/bjc.2011.326.

Cervarix: phase III trials

  • Lehtinen M, Paavonen J, Wheeler CM et al. For the HPV PATRICIA Study Group. Overall efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia grade 3 or greater: end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2011; 13(1): 89-99.
  • Wheeler CM, Castellsague X, Garland SM et al. For the HPV PATRICIA Study Group. Cross-protective efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: end-of-study (4-year) analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2011; 13(1): 100-10.

Gardasil: phase III trials

  • FUTURE II Study Group. Four year efficacy of prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine against low-grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010; 340: c3493.
  • Kjaer SK, Sigurdsson K, Iversen O-E et al. A pooled analysis of continued prophylactic efficacy of quadrivalent HPV (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res 2009; 2: 868-78.

 

[xhead] Curriculum

This topic falls under section 10.1 of the GP curriculum, Women’s Health.

 

[xhead] Online

 

Individual responses to patient questions from an expert panel

 

Provides information for doctors and patients in many European languages

 

  • Dr Szarewski has received conference sponsorship, honoraria and consultancy fees from GSK and Merck, Sharp and Dohme. She is an investigator in two GSK phase III HPV 16/18 vaccine trials
  • Women's Health conference, 27 September 2012, London.

 

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus